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TRIM69 exhibits potent and highly specific antiviral activity.
141
Because the anti-VSIV activity of type I IFN and Mx1 are well documented 142 (13, 16) , we were immediately struck by how potent the TRIM69-mediated inhibition 143 of VSIV was in our initial screen ( Figure 1D ). At the time that these experiments 144 were carried out, TRIM69 had not been ascribed any antiviral activity, so we 145 examined the ability of doxycycline inducible TRIM69 to inhibit a small panel of 
148
RVFV (35/74) and HIV-1 (NHG)) were unaffected by TRIM69 expression ( Figure 1E ).
149
It is well documented that many TRIM proteins are involved in antiviral signalling, 150 which can often be triggered by exogenous expression (5, (28) (29) (30) . Moreover, 151 exogenous or endogenous expression of many ISGs can promote cell death (31).
152
However, the highly specific antiviral activity of TRIM69, suggests that the antiviral 153 mechanism does not involve global processes such as cellular toxicity or the 154 induction of a polygenic antiviral state. Interestingly, a VSV-G (glycoprotein) 155 pseudotyped variant of HIV-1, that does not express an HIV-1 envelope glycoprotein, 156 was also insensitive to TRIM69-inhibition. This suggests that VSIV-inhibition occurs As well as lacking antiviral activity, shorter isoforms of TRIM5 can act as 196 dominant negative inhibitors of endogenous and exogenous TRIM5-mediated 197 restriction (34). We thus examined whether TRIM69 isoform B might similarly inhibit 198 the anti-VSIV activity of isoform A. When TRIM69 (isoform A) was constitutively 199 expressed, it conferred potent protection from VSIV-GFP infection ( Figure 3H 213 to ~17% (South Asian) in human populations. In light of this, we examined the ability 214 of all the major TRIM69 alleles (with a frequency >5% in at least one population) to 215 inhibit a small panel of vesiculoviruses ( Figure 4) . We cloned the seven main alleles 216 into our doxycycline inducible expression system ( Figure 4A -C) and challenged these 217 cells with a small panel of vesiculoviruses ( Figure 4C ). In spite of the amino acid 218 variation, all seven major alleles conferred potent protection from VSIV infection 219 ( Figure 4E ). Although some variation in the magnitude of protection was observed, 220 we attributed this to slight variations in TRIM69 expression levels, as opposed to 221 variation in the anti-VSIV activity of the different alleles ( Figure 4C ). TRIM69 again 222 exhibited exquisite antiviral specificity and none of the TRIM69 alleles inhibited VSV
223
New Jersey (VSNJV) or chandipura virus (CHNV-GFP) ( Figure 4F ,G).
224
Because multiple TRIM69 alleles currently circulate in human populations and 225 antiviral TRIM proteins can possess strong signatures of positive selection (36), we 226 conducted positive selection analysis of TRIM69 sequences from primates. We 227 retrieved and aligned the TRIM69 coding region from 18 primate species 228 representing >40 million years of divergent evolutionary pressures (37). Using the 229 maximum likelihood approach in PAML (38), we tested whether models that permit 230 positive selection on individual codons (dN/dS>1) were a better fit to these data, than 231 models that do not allow positive selection. In each case, permitting sites to evolve 232 under positive selection gave a better fit ( Figure 5AB ), with a high proportion of 233 codons exhibiting dN/dS ratios greater than 1 (32.8% with average dN/dS=1.9).
234
These analyses identified six residues exhibiting relatively strong signatures of 235 positive selection ( Figure 5AB ). One of the sites identified using this approach 236 (S404) is within the SPRY domain (the domain that forms the host-pathogen 237 interface that defines the antiretroviral specificity of TRIM5 (36)). These analyses 238 suggest that whilst the majority of sites (67.2%) in TRIM69 have evolved under 239 purifying selection (in order to maintain the overall structure and function of TRIM69), 240 positive selection has likely occurred at specific sites perhaps influencing the antiviral 241 activity of TRIM69 (36).
242
Based on the signatures of positive selection at the TRIM69 locus in primates,
243
we hypothesized that divergent TRIM69 proteins might exhibit divergent antiviral 244 specificities. We therefore cloned a variety of TRIM69 orthologs from a selection of 245 species (including primates and a variety of other mammals) into our doxycycline 246 inducible expression system. Similar to human TRIM69, orthologs from rhesus 247 macaques, rats, cows, alpacas, dogs, ferrets and horses all potently inhibited VSIV 248 infection ( Figure 5C ). The magnitude of inhibition was variable, but we attributed the 249 majority of this variability to different TRIM69 expression levels ( Figure 5C ).
250
Strikingly, murine TRIM69 did not inhibit VSIV, despite being expressed at higher 251 levels than multiple inhibitory orthologs ( Figure 5C ). Furthermore, the anti-VSIV 252 activity of TRIM69 has apparently been lost in the Mus genus as TRIM69 orthologs 253 from M. caroli and M. pahari were non-inhibitory, whereas rat TRIM69 potently 254 inhibited VSIV ( Figure 5D ). This is not simply due to the murine orthologs lacking 255 specific cofactors/interactions within human cells, as stable expression of murine 256 TRIM69 (M. musculus) in mouse cells indicated that murine TRIM69 still possessed 257 no apparent anti-VSIV activity ( Figure 5E ).
Crucially, murine TRIM69 was 258 abundantly expressed in these cells and human TRIM69 conferred potent protection 259 from VSIV infection, when expressed at similar levels in the identical murine 260 background ( Figure 5EF ). Thus, while murine cells support TRIM69-mediated anti-
261
VSIV activity, murine orthologs of TRIM69 have lost the ability to inhibit VSIV.
262
We also challenged the species variants of TRIM69 with related 263 vesiculoviruses (VSNJV and CHNV), but none of the orthologs considered 264 possessed substantial antiviral activity against these viruses ( Figure 5GH ).
266
The VSIV phosphoprotein confers sensitivity/resistance to TRIM69. The short 267 generation times inherent to the lifecycles of most viruses means that resistance to 268 inhibition can be rapidly selected in vitro (5, 26, 39, 40) . These in vitro evolution 269 approaches can rapidly identify antiviral sensitivity/resistance determinants in viruses 270 targeted by antiviral factors (39, 41) . We used a diverse swarm of replication 271 competent full-length VSIV-GFP (FL VSIV-GFP) (42) that had been propagated in 272 mammalian cells. This parental virus stock was potently inhibited by TRIM69
273
following overnight infection ( Figure 6A ). We used this virus to inoculate a culture 274 expressing TRIM69, using a dose where <1% of cells were GFP-positive following 275 overnight incubation. Four days later, VSIV had begun to overwhelm this culture and 276 the supernatant was filtered and transferred to a new culture (also induced to 277 express TRIM69). In this second passage, VSIV replicated far more efficiently in the 278 presence of TRIM69, suggesting resistance had emerged. Such rapid acquisition of 279 resistance is a documented property of VSIV populations and VSIV fitness has been 280 previously shown to increase >1000-fold in a single passage (within a new cellular 281 environment) (43). We titrated the filtered supernatant containing the TRIM69-282 passaged swarm, in the presence and absence of TRIM69, and observed that VSIV 283 had been selected to resist TRIM69 inhibition ( Figure 6A ). We sequenced the viral 284 population and observed four substitutions that had been selected to near uniformity 285 in the viral swarm ( Figure 6BC ). These substitutions included two synonymous 286 changes and two nonsynonymous substitutions. Because we had previously 287 observed that the VSV-G protein was not targeted by TRIM69 when used to 288 pseudotype HIV-1 ( Figure 1E ), we reasoned that one substitution, E92K in VSV-G,
289
was unlikely to confer resistance to TRIM69. This left only one non-synonymous 290 substitution, D70Y, located in the VSIV phosphoprotein (P-protein) that might confer 291 TRIM69-resistance. We mutated this residue in isolation, in the FL VSIV-GFP 292 plasmid background and rescued the parental and D70Y mutant viruses. While the 293 rescued parental virus was potently inhibited by TRIM69, the P-protein D70Y mutant 294 was completely insensitive to inhibition by TRIM69 ( Figure 6D are susceptible and permissive to both DENV-2 and VSIV, we selected these cells as 310 the background for our experiments. We generated Vero cells that stably expressed 311 human, rat or mouse TRIM69 and infected these cells with a titrated challenge of 312 DENV-2 or VSIV-GFP. We used the New Guinea C strain of DENV-2 as this strain 313 was previously reported to be inhibited by TRIM69 (32) 
317
Because the previously published work had not specifically investigated 318 exogenous TRIM69 expression in Vero cells, we examined whether TRIM69 319 expression in HEK 293T cells would induce the degradation of transfected NS3 but 320 not NS3 K104R (recapitulating published observations) (32) . Surprisingly, TRIM69 321 had no effect on NS3 expression levels ( Figure 7G ). In contrast, VSIV was potently 322 blocked in parallel experiments using the equivalent cells ( Figure 7H ). We conclude 323 that DENV-2 is not always inhibited by TRIM69, even under conditions where 324 TRIM69 exhibits substantial antiviral activity against VSIV.
326
The anti-VSIV activity of TRIM69 is not dependent upon IFN-signalling or E3 327 ubiquitin ligase activity. TRIM69 has a RING domain predicted to have E3 328 ubiquitin ligase activity. Moreover, proteasomal degradation has previously been 329 reported to be involved in the TRIM69-mediated inhibition of DENV-2 (32). In 330 addition, TRIM69 isoform B (which lacks a RING domain) possess no anti-VSIV 331 activity ( Figure 3C ). We therefore considered whether inhibiting proteasomal 332 degradation might affect TRIM69 antiviral activity. As a less toxic alternative to 333 MG132, we used bortezomib (Bort), an inhibitor of the 26S proteasome, which is also 334 licensed for clinical use (44, 45) . In order to validate the efficacy of inhibition, we 335 transduced cells with a lentiviral vector encoding ubiquitin fused to GFP. This fusion 336 protein is rapidly degraded and GFP expression is not visible under normal culture 337 conditions ( Figure 8AB ). However, when the 26S proteasome was inhibited by 
393
The most surprizing aspect of the highly specific anti-VSIV activity of TRIM69 394 was that DENV-2, previously reported to be inhibited by TRIM69 (32), was not 395 inhibited in our experiments. Importantly, this lack of TRIM69-sensitivity was 396 observed whilst parallel cultures (of the equivalent cells) fiercely resisted VSIV 397 infection. There are many possible explanations for these apparently contradictory 398 observations. The most likely explanation is that due to the highly specific nature of 399 TRIM69-mediated inhibition, some aspect of the virus strain, cellular background or 400 method used has led to DENV-2 appearing insensitive to inhibition (in our 401 experiments). We were careful to use the same strain as used previously 402 (specifically the New Guinea C strain, which we obtained from Public Health 403 England). We confirmed the presence of the 'TRIM69-sensitive' lysine (at position 404 104 of NS3) in our virus stocks and more work will be required to understand why we 405 did not observe DENV-2 inhibition in the face of antiviral TRIM69. Importantly, with 406 both VSIV and DENV-2, a single amino acid substitution conferred resistance to 407 TRIM69. Thus, seemingly minor differences in viral strains could easily reconcile 408 these apparently contradictory observations.
409
Although we do not know how TRIM69 impedes VSIV, the block must occur 
414
the D70Y mutation in the VSIV phosphoprotein does provide some potential 415 mechanistic clues. Importantly, D70 is present in a region of VSV-P that is heavily 416 phosphorylated (phosphorylation of residues 60, 62 and 64 has been described) (51).
417
Phosphorylation of these sites has been proposed to be important in P-protein 418 dimerization and interaction with the L-protein (large polymerase protein) (52-56) and 419 phosphorylation of this region is essential for functional RNA dependent RNA 420 polymerase activity (57). Because tyrosine residues are known to be phosphorylated 421 in the VSV-P protein (58), it is therefore tempting to speculate that a tyrosine at 422 position 70 could be phosphorylated, and that this phosphorylation somehow 423 overcomes the block mediated by TRIM69. A speculative mechanism that involves 424 TRIM69-mediated inhibition of VSIV RNA dependent RNA polymerase activity (by 425 inhibiting the association of P and L-proteins) would be entirely consistent with the 426 early block described herein.
427
The N-terminal region of vesiculoviral P-proteins are relatively divergent, 
435
VSIV in vivo, the D70Y mutation must be deleterious for some other reason and is 436 therefore negatively selected (despite conferring resistance to TRIM69).
437
Our failure to identify any viruses other than VSIV that were inhibited by 438 TRIM69, limited our ability to identify whether species variants of TRIM69 possess 439 divergent antiviral specificities. Despite this, differential activity was observed as 440 anti-VSIV activity has apparently been lost in the Mus genus. Whether murine
441
TRIM69s have been selected to target other viruses or whether murine orthologs 442 have no antiviral activity at all remains to be determined. Thus, murine TRIM69 443 might be an active antiviral factor selected to target a divergent spectrum of viruses, 444 in a way that prevents it from inhibiting VSIV. The rat and mouse TRIM69 variants
445
were the closest orthologs we tested, that displayed differential activity against VSIV, 446 and these species variants differ at 38 amino acid positions. Despite detecting site-447 specific signatures of positive selection in TRIM69, all of the signature sites are 448 conserved between rats and mice. Thus, the genetic basis of the differential anti-
449
VSIV activity observed in rodent TRIM69 variants is currently unknown.
450
The lack of anti-VSIV activity conferred by murine TRIM69 could have 
475
The VSIV-GFP virus (rVSVΔG-GFP) competent to undergo a single round of 476 infection but not encoding the VSV-G envelope (rVSV-ΔG-GFP decorated with VSV-
477
G expressed in trans) system was used (27). Virus stocks were generated as 
486
The D70Y mutant (VSV-P) was made using the Agilent QuikChange Lightning 
636
For assays using GFP-encoding viruses, cells were seeded in 96 well plates.
637
Adherent and semi-adherent cells were seeded 24 hours before challenge or 638 treatment whereas suspension cells were seeded immediately prior to infection or 
